<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic kidney disease in children: Definition, epidemiology, etiology, and course</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic kidney disease in children: Definition, epidemiology, etiology, and course</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic kidney disease in children: Definition, epidemiology, etiology, and course</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley A Warady, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Darcy K Weidemann, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic kidney disease (CKD) refers to a state of irreversible kidney damage and/or reduction of kidney function that is associated with a progressive loss of kidney function over time.</p><p>The etiology, epidemiology, and progression of CKD in children will be reviewed here. The clinical presentation, evaluation, management, and complications of CKD in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/6134.html" rel="external">"Chronic kidney disease in children: Clinical manifestations and evaluation"</a> and  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management"</a> and  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS AND DIAGNOSIS</span><span class="headingEndMark"> — </span><strong>Chronic kidney disease (CKD)</strong> is defined as the presence of structural or functional kidney damage that persists over a minimum of three months. Functional damage is typically characterized by a sustained reduction of estimated glomerular filtration rate (eGFR), a persistent elevation of urinary protein excretion, or both.</p><p>This broad definition was used by the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines to define the diagnostic criteria and classification of pediatric CKD [<a href="#rid1">1</a>]. The KDIGO diagnosis criteria and classification are the standard used in clinical practice, research, and public health in the care of children with CKD and will be used throughout this topic.</p><p>The <strong>diagnosis of pediatric CKD</strong> is based on fulfilling one of the following criteria [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>GFR of less than 60 mL/min per 1.73 m<sup>2</sup> for greater than three months with implications for health regardless of whether other CKD markers are present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GFR greater than 60 mL/min per 1.73 m<sup>2</sup> that is accompanied by evidence of structural damage or other markers of kidney function abnormalities, including proteinuria, albuminuria, renal tubular disorders, or pathologic abnormalities detected by histology or inferred by imaging. This category also includes patients with functioning kidney transplants.</p><p></p><p class="headingAnchor" id="H99304645"><span class="h1">STAGING: RISK STRATIFICATION</span><span class="headingEndMark"> — </span>CKD staging guides management by stratifying the risk for progression and complications of CKD. Risk stratification guides the recommended intensity of monitoring and management for CKD progression and comorbid conditions associated with CKD. In adults, staging is based on the cause of the disease, glomerular filtration rate (GFR), and degree of albuminuria (see  <a class="medical medical_review" href="/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults"</a>). However, staging for clinical care of children with CKD is primarily based on estimated (eGFR). Ongoing research is focused on developing comparable information to adult data to incorporate the degree of proteinuria and etiology to improve risk stratification for pediatric CKD. (See <a class="local">'Evaluation of proteinuria'</a> below.)</p><p class="headingAnchor" id="H530618102"><span class="h2">Glomerular filtration rate</span><span class="headingEndMark"> — </span>GFR represents the sum of the filtration rates of all of the functioning nephrons. A reduction in GFR implies a decrease in the number of functioning nephrons due to underlying disease/injury or initial reduction due to congenital disorder [<a href="#rid2">2</a>]. For patients two years of age and older, the severity of CKD is categorized by the KDIGO clinical practice guidelines into stages based on estimated GFR  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>) (see <a class="local">'Estimated glomerular filtration rate'</a> below) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>G1 – Normal GFR (≥90 mL/min per 1.73 m<sup>2</sup>)</p><p class="bulletIndent1"><span class="glyph">●</span>G2 – GFR between 60 and 89 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G3a – GFR between 45 and 59 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G3b – GFR between 30 and 44 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G4 – GFR between 15 and 29 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>G5 – GFR &lt;15 mL/min per 1.73 m<sup>2</sup> (kidney failure)</p><p></p><p>End-stage kidney disease defines a state of permanent loss of kidney function, generally requiring long-term dialysis or kidney transplant to sustain life and is categorized as stage G5 with a GFR below 15 mL/min per 1.73 m<sup>2</sup>. (See  <a class="medical medical_review" href="/d/html/16179.html" rel="external">"Overview of kidney replacement therapy for children with chronic kidney disease"</a>.) </p><p class="headingAnchor" id="H3914567900"><span class="h3">Children less than two years of age</span><span class="headingEndMark"> — </span>Normal levels of GFR vary with age, sex, and body size. GFR increases with maturation from infancy and approaches the adult mean value by two years of age  (<a class="graphic graphic_table graphicRef55965" href="/d/graphic/55965.html" rel="external">table 2</a>) [<a href="#rid3">3,4</a>]. As a result, the above classification is not applicable to children less than two years of age, because their GFR is normally lower than the values of GFR of older individuals and would incorrectly place them in a stage of disease characterized by greater kidney impairment than their actual kidney function [<a href="#rid5">5</a>]. As an example, a six-month-old infant with normal kidney function would be incorrectly classified as having GFR category G2 disease because the mean GFR for this age is normally below 89 mL/min per 1.73 m<sup>2</sup>.</p><p>Although the above schema cannot be used, an estimated GFR based on serum creatinine can be compared with normative age-appropriate values to detect kidney impairment in toddlers and infants with CKD  (<a class="graphic graphic_table graphicRef116099" href="/d/graphic/116099.html" rel="external">table 3</a>). Values more than 1 standard deviation (SD) below the mean should raise concern and prompt continued monitoring of kidney function [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate reduction is defined as an age-specific GFR value between 1 to 2 SD below the mean</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe reduction is defined as an age-specific GFR value &gt;2 SD below the mean</p><p></p><p class="headingAnchor" id="H99304709"><span class="h3">Estimated glomerular filtration rate</span><span class="headingEndMark"> — </span>Clinically, an estimated GFR is used as a measure of kidney function. The GFR is typically calculated from an individual's serum creatinine level and height and is a more accurate assessment of function than using serum creatinine alone. Using formulas to determine GFR is also easier in a clinical setting compared with assessing GFR by clearance of a urinary marker.</p><p class="headingAnchor" id="H716473967"><span class="h4">Calculated glomerular filtration rate</span><span class="headingEndMark"> — </span>Serum creatinine-based formulas are generally used to estimate GFR in children with CKD and are typically calculated using the child's height, serum creatinine, and a constant "k" that is based on the creatinine assay used by the clinical laboratory performing the test (<a class="calc calc_professional" href="/d/html/13424.html" rel="external">calculator 1</a>):</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">eGFR = "k" × Height in cm / serum creatinine</p></div></div><p></p><p>The constant "k" used in the pediatric equation is dependent on the laboratory assay that measures serum creatinine:</p><p class="bulletIndent1"><span class="glyph">●</span>If the <strong>Jaffe method for creatinine</strong> is used, the value of "k" is directly proportional to the muscle component of body and varies with age and, in adolescents, with the sex of the patient [<a href="#rid6">6-8</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preterm infants up to one year of age – The value for "k" is 0.33</p><p class="bulletIndent2"><span class="glyph">•</span>Term infants up to one year of age – The value for "k" is 0.45</p><p class="bulletIndent2"><span class="glyph">•</span>Children of both sexes and adolescent females – The value for "k" is 0.55</p><p class="bulletIndent2"><span class="glyph">•</span>Adolescent males – The value for "k" is 0.77</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the <strong>enzymatic method</strong> <strong>for creatinine</strong> is used, the value of "k" is equal to 0.413 for serum creatinine units in mg/dL and 36.52 for serum creatinine units in mcmol/L. [<a href="#rid9">9</a>]. This formula has only been validated for a range of GFR between 15 and 75 mL/min per 1.73 m<sup>2</sup> in children &lt;18 years of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The measurement of serum cystatin C is clinically available and standardized against International Federation of Clinical Chemistry (IFCC)-approved reference material. Newer and more precise GFR-estimating equations based on enzymatic creatinine and IFCC-standardized cystatin C have been published by the Chronic Kidney Disease in Children Study (CKiD study) [<a href="#rid10">10</a>]. These <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fckid-gfrcalculator.shinyapps.io%2FeGFR&amp;token=Jg5YMvd8AhVxbyA8UCl4y3D9Z72phVuxWARrH0Dw34WP3JlB7yalCcrNVI5f%2B4lZM%2BnpWZpma29YZL3Aa8tzog%3D%3D&amp;TOPIC_ID=6115" target="_blank">newer equations developed by CKiD</a> include age- and sex-dependent values for "k" for children and young adults with CKD up to age 25 years old.</p><p></p><p>The use of the creatinine-based GFR estimating formulas is limited in patients with an unusual dietary intake (eg, vegetarian diet or creatinine supplements) or in those with decreased muscle mass (eg, amputation, malnutrition, or muscle wasting) [<a href="#rid11">11</a>]. In these circumstances, determining the GFR using a serum creatinine measurement in conjunction with a timed urine collection, as discussed below, or the use of serum cystatin C may be more appropriate [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H704216052"><span class="h4">Other methods</span><span class="headingEndMark"> — </span>The following methods used to measure GFR are based on determining the clearance of a filtration marker and are not practical for routine clinical use. (See  <a class="medical medical_review" href="/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Inulin, a physiologically inert substance that is freely filtered at the glomerulus, has been the gold standard of marker. However, it requires continuous intravenous infusion, multiple blood samples, and, at times, bladder catheterization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Creatinine clearance is determined by serum creatinine and a timed urine collection for creatinine clearance; however, the collection is often inconvenient for families and inaccurate due to missed samples, episodes of incontinence, or voiding problems.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other methods include single-injection techniques for plasma disappearance of <a class="drug drug_pediatric" data-topicid="111397" href="/d/drug information/111397.html" rel="external">iohexol</a>, inulin, and other exogenous filtration markers.</p><p></p><p class="headingAnchor" id="H3975089121"><span class="h2">Evaluation of proteinuria</span><span class="headingEndMark"> — </span>The KDIGO guidelines use the level of albuminuria to predict mortality and kidney outcomes in adults with CKD (see  <a class="medical medical_review" href="/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults", section on 'Albuminuria'</a>). Although similar direct data in children are lacking, there is good evidence that the presence and severity of proteinuria (as measured by urinary protein-to-creatinine ratio) are predictive of declining kidney function in children [<a href="#rid13">13-16</a>]. In children &gt;2 years old, a normal value for urinary protein-to-creatinine ratio is no more than 0.2 mg/mg [<a href="#rid17">17</a>]. In term infants, reported urinary protein-to-creatinine values are higher with values up to 1.4 mg/mg but more data are needed to confirm the normal values for infants [<a href="#rid18">18</a>]. Urinary albumin excretion is similar to urine protein-to-creatinine ratio in its capacity to predict CKD progression in children [<a href="#rid15">15</a>].</p><p>Urinary protein excretion (as measured by urinary protein-to-creatinine ratio) is used more frequently than albuminuria in pediatric CKD because the majority of children with CKD have nonglomerular congenital kidney conditions where albuminuria testing does not identify high levels of urine total protein loss due to tubular proteinuria and diabetic nephropathy, a major etiology for CKD in adults characterized by albuminuria, is uncommon in children. Based on published pediatric data, there is increasing evidence that the presence and severity of proteinuria (rather than albuminuria) are predictive of declining kidney function in children [<a href="#rid13">13-16,19</a>]. However, one study from the CKiD study reported urinary albumin excretion was similar to urine protein-to-creatinine ratio in its capacity to predict CKD progression in children [<a href="#rid15">15</a>]. (See <a class="local">'Progression of chronic kidney disease'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H36557174"><span class="h2">Reported global incidence</span><span class="headingEndMark"> — </span>Obtaining accurate data on the epidemiology of pediatric CKD is challenging. The reported number of children with pediatric CKD is likely underestimated because earlier stages of CKD are usually asymptomatic and lead to underdiagnosis. Additionally, there may be under-reporting due to inadequate health services in resource-limited areas. As a result, it is difficult to compare rates of childhood CKD throughout the world due to the variability of available health resources, both for the care of children with CKD as well as for tracking and collecting accurate population-based data and the use of different definitions [<a href="#rid20">20,21</a>]. Furthermore, published information is often based on reports from major referral centers, and it is uncertain whether these data truly reflect population-based risks.</p><p>These limitations were noted in a review article that provided the following population-based estimates of moderate to severe CKD or end-stage kidney disease (ESKD) in children defined as requiring kidney replacement therapy (KRT) [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate to severe CKD – Estimated median annual incidence of per million of age-related population (pmarp) varied as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Europe – 11.9 cases pmarp.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Latin America – Rates ranged from 2.8 to 15.8 cases pmarp.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sub-Saharan Africa, which has the most limited health resources, the lowest published rate of CKD was noted from single-center studies and ranged from 1 to 3 cases pmarp.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>KRT – The annual incidence of ESKD requiring KRT varied and is most likely directly related to the availability of KRT for children in the reporting countries:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New Zealand – 18 cases pmarp</p><p class="bulletIndent2"><span class="glyph">•</span>United States – 15.5 cases pmarp</p><p class="bulletIndent2"><span class="glyph">•</span>Western Europe and Australia – 9.5 pmarp</p><p class="bulletIndent2"><span class="glyph">•</span>Russia – &lt;4 cases pmarp</p><p></p><p class="headingAnchor" id="H3651377524"><span class="h2">Race and genetics</span><span class="headingEndMark"> — </span>Registry data from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) and the Australia and New Zealand Dialysis and Transplant Registry reported an increased risk for CKD in ethnic minority populations.</p><p class="bulletIndent1"><span class="glyph">●</span>In North America, the rate of CKD is two to three times higher in Black compared with White children [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Australia and New Zealand, children with indigenous ethnicity (eg, Aborigines and Maoris) have a higher risk for acute kidney injury and certain types of CKD. The rates of ESKD in the indigenous populations compared with the nonindigenous populations are similar under age 14 years but increase significantly after 15 years of age [<a href="#rid23">23</a>].</p><p></p><p>In the Black population, the genotype of apolipoprotein L1 (<em>APOL1</em>) might explain the increased risk for CKD. The high-risk genotype for <em>APOL1</em> (homozygous for the risk alleles "G1" or "G2" or G1G2 compound heterozygosity) is associated with an increased risk for the development of glomerular disease, particularly focal segmental glomerulosclerosis (FSGS), compared with those with a low-risk genotype (having 0 or 1 risk alleles) [<a href="#rid24">24</a>]. In a combined analysis of the Chronic Kidney Disease in Children (CKiD) study and Nephrotic Syndrome Study Network (NEPTUNE) of 104 Black children with glomerular disease, children with the high-risk genotype experienced a faster decline in kidney function over time compared with children with the low-risk genotype [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1371574928"><span class="h2">Sex</span><span class="headingEndMark"> — </span>The incidence and prevalence of pediatric CKD are greater in males than females [<a href="#rid22">22,25,26</a>]. The increased risk of CKD in males is due to their higher incidence of congenital anomalies of the kidney and urinary tract (CAKUT), including obstructive uropathy, kidney dysplasia, kidney hypoplasia, and prune-belly syndrome.</p><p class="headingAnchor" id="H298655952"><span class="h2">Age</span><span class="headingEndMark"> — </span>Patients present with CKD throughout childhood. In the NAPRTCS chronic renal insufficiency (CRI) database, which contains over 7000 patients with CKD, the age distribution at presentation of CKD was as follows [<a href="#rid22">22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Below 12 months of age – 15 percent</p><p class="bulletIndent1"><span class="glyph">●</span>12 to 23 months – 5.2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>2 years of age to below 6 years of age – 15.7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>6 years of age to below 13 years of age – 32.1 percent</p><p class="bulletIndent1"><span class="glyph">●</span>13 years of age to below 18 years of age – 28.3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>18 to 21 years of age – 3.7 percent</p><p></p><p class="headingAnchor" id="H6"><span class="h1">ETIOLOGY</span></p><p class="headingAnchor" id="H1555888052"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>The distribution of causes of pediatric CKD varies by age [<a href="#rid22">22,25</a>]. Congenital causes of kidney disease present and are typically diagnosed during infancy or childhood, although a growing percentage are diagnosed by antenatal detection [<a href="#rid27">27</a>]. The diagnosis of CKD due to acquired kidney disease tends to be more common in later childhood and adolescence.</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital anomalies of the kidney and urology tract (CAKUT) account for 60 percent of pediatric CKD cases and are more prevalent in younger patients. These disorders include kidney aplasia/hypoplasia/dysplasia, reflux nephropathy, obstructive uropathy anomalies (eg, posterior urethral valves) and polycystic kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular causes account for 10 to 20 percent of children with CKD [<a href="#rid22">22,25</a>]. A glomerular etiology is more common in older children, accounting for approximately 45 percent of cases in patients greater than 12 years of age in the United States.</p><p></p><p class="bulletIndent1">In the United States, focal segmental glomerulosclerosis (FSGS) was the most common glomerular disorder, occurring in 9 percent of all pediatric CKD cases. Black children were three times more likely to develop FSGS than White patients, and FSGS was the cause of CKD in one-third of Black adolescent patients. (See <a class="local">'Race and genetics'</a> above.)</p><p></p><p class="bulletIndent1">Other glomerular causes of CKD in children include hemolytic uremic syndrome and secondary glomerular disease (eg, systemic lupus nephritis). Unlike in adults, diabetic nephropathy and hypertension are rare causes of CKD in children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other disorders account for 20 to 30 percent of pediatric CKD cases and include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic disorders such as cystinosis, oxalosis, and hereditary nephritis (also referred to as Alport syndrome)</p><p class="bulletIndent2"><span class="glyph">•</span>Interstitial nephritis</p><p class="bulletIndent2"><span class="glyph">•</span>Unidentified or unknown primary underlying etiology</p><p></p><p class="headingAnchor" id="H1392923448"><span class="h2">End-stage kidney disease</span><span class="headingEndMark"> — </span>Although glomerular disease represents a smaller percentage of the etiology of overall CKD, these disorders account for a larger proportion of the underlying cause for pediatric end-stage kidney disease (ESKD) patients. This is due to the rapid rate of CKD progression in patients with these disorders compared with patients with nonglomerular causes of CKD [<a href="#rid13">13</a>].</p><p>In the 2023 report from the United States Renal Data System (USRDS), the following distribution of causes of ESKD in children (ages 0 to 17 years) was reported for 2017 to 2021 [<a href="#rid28">28</a>]. Note that primary and secondary glomerular diseases accounted for approximately one-third of children with ESKD.</p><p class="bulletIndent1"><span class="glyph">●</span>Primary glomerular disease – 21.2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital anomalies of the kidney and urinary tract (CAKUT) – 28.3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Cystic/hereditary/congenital diseases – 12.2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary glomerular disease/vasculitis – 8.3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial nephritis/pyelonephritis – 4.7 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Transplant complications – 1.5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes – 0 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Neoplasms/tumors – 0.8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Miscellaneous conditions – 12.8 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Etiology uncertain – 6.2 percent</p><p></p><p class="headingAnchor" id="H7"><span class="h1">PROGRESSION OF CHRONIC KIDNEY DISEASE</span></p><p class="headingAnchor" id="H3886343956"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Acquired or congenital reduction in nephron number results in CKD. The progression of CKD is characterized by the progressive loss of kidney function independent of the initiating cause of CKD. It is important to understand the factors associated with progression of CKD to identify management strategies to prevent or slow the decline of kidney function to end-stage kidney disease (ESKD). Furthermore, it is essential to treat comorbid complications and to recognize the effect of CKD on growth and development and other chronic conditions such as cardiovascular disease. (See  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management", section on 'Prevent or slow progression of kidney disease'</a>.)</p><p class="headingAnchor" id="H3230800339"><span class="h3">Proposed mechanisms</span><span class="headingEndMark"> — </span>The progression of CKD to ESKD is largely due to secondary factors that are unrelated to the initial disease. These include systemic and intraglomerular hypertension, glomerular hypertrophy, the intrarenal precipitation of calcium phosphate, hyperlipidemia, and altered prostanoid metabolism. CKD progression is characterized histopathologically by focal segmental glomerulosclerosis (FSGS), which is called secondary FSGS, interstitial fibrosis, peritubular capillary rarefaction, and inflammation [<a href="#rid29">29</a>]. Thus, despite the initial injury being ameliorated or treated, the parenchymal scarring of CKD is progressive. The pathophysiologic mechanisms causing CKD progression is an area of active research and proposed mechanisms are discussed separately. (See  <a class="medical medical_review" href="/d/html/7181.html" rel="external">"Secondary factors and progression of chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H834735013"><span class="h2">Pediatric factors</span><span class="headingEndMark"> — </span>In children, multiple factors, in addition to those that are commonly observed in adults with CKD (systemic hypertension, proteinuria, anemia, hyperphosphatemia, hypocalcemia, and hypovitaminosis-D), are associated with CKD progression [<a href="#rid13">13,30-34</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neonatal factors</strong> – The long-term effects on kidney function need to be elucidated when kidney injury occurs in the neonatal period. Prematurity and fetal growth restriction are both risk factors for CKD, as injury occurs during the time period of continued nephron development, which is completed at 35 weeks gestation [<a href="#rid35">35,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth</strong> – The rate of CKD progression is usually greatest during the periods of rapid growth, particularly in puberty, when the sudden increase in body mass results in a rise in the filtration demands of the remaining nephrons [<a href="#rid37">37</a>]. As a result, children with CKD should be closely monitored during adolescence for an accelerated progression of CKD. In addition to the increase in body mass, hormonal changes during puberty may also contribute to the rapid decline in kidney function seen in adolescence. It remains to be seen if effective interventions can be identified to modify the acceleration of CKD decline during these periods of rapid growth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Underlying primary disease</strong> – More rapid CKD progression is observed in children with glomerular disease versus those with nonglomerular disease [<a href="#rid13">13,16</a>]. Data from the Chronic Kidney Disease in Children (CKiD) cohort identified elevated urinary protein excretion (urinary protein-to-creatinine ratio &gt;2 mg/mg), hypoalbuminemia, and elevated blood pressure (BP), which are more commonly seen in children with <strong>glomerular disease</strong>, as risk factors for CKD progression [<a href="#rid13">13</a>]. Of note, the rate of CKD progression increased with the level of proteinuria in patients who were normotensive; however, a decline in GFR was noted irrespective of the level of proteinuria among children with an elevated systolic BP.</p><p></p><p class="bulletIndent1">For children with <strong>nonglomerular etiology</strong>, additional risk factors associated with significant CKD progression included dyslipidemia, male sex, anemia, proteinuria, and systolic BP level  (<a class="graphic graphic_figure graphicRef101704" href="/d/graphic/101704.html" rel="external">figure 1</a>) [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic factors</strong> – As noted above, genetic and ethnic predisposition may influence the rate of kidney function decline. As an example, the <em>APOL1</em> high-risk genotype among Black patients increases the susceptibility to CKD and may contribute to a faster rate of CKD progression compared with groups of other ancestry. (See  <a class="medical medical_review" href="/d/html/7181.html" rel="external">"Secondary factors and progression of chronic kidney disease", section on 'Genetic factors'</a>.)</p><p></p><p>Despite identifying the above risk factors for pediatric CKD, large knowledge gaps remain in understanding pediatric CKD progression. Several multicenter pediatric CKD trials and cohort studies have been established to improve our understanding of pediatric CKD progression and hopefully identify predictive markers for CKD progression that will be helpful in slowing the CKD progression.</p><p class="headingAnchor" id="H2516804021"><span class="h2">Interventions</span><span class="headingEndMark"> — </span>Interventions to slow CKD progression that are generally accepted standard of care include BP control and measures to reduce proteinuria [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/6085.html" rel="external">"Chronic kidney disease in children: Overview of management", section on 'Slow progression of chronic kidney disease'</a>.)</p><p class="headingAnchor" id="H3486268633"><span class="h3">Blood pressure control</span><span class="headingEndMark"> — </span>Although some of the risk factors noted above might be amenable to intervention, BP control in children has been the only risk factor that has been assessed in the setting of a randomized controlled trial.</p><p>The effect of high BP on progression of CKD is illustrated by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Effect of Strict Blood Pressure Control and ACE Inhibition on CRF Progression in Pediatric Patients (ESCAPE) trial of 468 pediatric patients with CKD stages 2 to 4 conducted from 1998 to 2001 across the European Union, CKD progression was slower in children who received intensified BP treatment to maintain a 24-hour mean arterial pressure below the 50<sup>th</sup> age-related percentile compared with those in whom treatment was targeted to maintain BP levels between the 50<sup>th</sup> and 90<sup>th</sup> percentile [<a href="#rid38">38</a>]. All patients in this trial received the same fixed dose of an ACE inhibitor, with the addition of other BP medications as needed to achieve target BP levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Longitudinal data from the CKiD study of 679 children with moderate CKD revealed that patients with 24-hour ambulatory blood pressures in the highest MAP category (&gt;90<sup>th</sup> percentile) experienced the fastest CKD progression as compared with individuals with blood pressures in the lowest MAP category (&lt;50<sup>th</sup> percentile) [<a href="#rid39">39</a>]. The effect of higher BP on the composite outcome of renal replacement therapy or 50 percent decline in renal function appeared to be greater for children with glomerular disease (hazard ratio [HR] 3.23 95% CI, 1.34-7.79) than for those with non-glomerular disease (HR 1.88, 95% CI, 1.03-3.44) [<a href="#rid39">39</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Chronic kidney disease (CKD) refers to a state of irreversible kidney damage and/or reduction of kidney function that generally continues to progress over time. It is defined as the presence of structural or functional kidney damage that persists over a minimum of three months. (See <a class="local">'Definitions and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic criteria</strong> – In our practice, the diagnostic criteria that are used is based on the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 clinical practice guidelines that require fulfilling <strong>one</strong> of the following clinical criteria (see <a class="local">'Definitions and diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glomerular filtration rate (GFR) of less than 60 mL/min per 1.73 m<sup>2</sup> for greater than three months with implications for health regardless of whether other CKD markers are present.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GFR greater than 60 mL/min per 1.73 m<sup>2</sup> that is accompanied by evidence of structural damage or other markers of functional kidney abnormalities including proteinuria, albuminuria, renal tubular disorders, or pathologic abnormalities detected by histology or inferred by imaging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CKD stages</strong> – CKD staging guides management by stratifying the risk for progression and complications of CKD.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Staging for children between 2 and 18 years of age</strong> – In our practice, we stage patients by their level of GFR for children between 2 and 18 years of age (<a class="calc calc_professional" href="/d/html/13424.html" rel="external">calculator 1</a>)  (<a class="graphic graphic_table graphicRef89808" href="/d/graphic/89808.html" rel="external">table 1</a>). Clinically, the assessment of proteinuria is an important consideration in the management of a child with CKD. However, further work is needed to validate the inclusion of proteinuria for staging in a non-study cohort of pediatric patients with CKD. (See <a class="local">'Staging: Risk stratification'</a> above and <a class="local">'Estimated glomerular filtration rate'</a> above and <a class="local">'Evaluation of proteinuria'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Staging for children &lt;2 years of age</strong> – Children under two years of age do not fit within the KDIGO classification system, because they normally have a lower GFR even when corrected for body surface area. In these patients, an estimated GFR (eGFR) based on serum creatinine can be compared with normative age-appropriate values. A value &gt;1 standard deviation (SD) below the mean should raise concern and prompt more intensive monitoring. (See <a class="local">'Children less than two years of age'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – In children, the incidence of CKD is underreported due to the asymptomatic nature of the early stages of CKD. In some countries, the data may also be compromised by limited health resources that can systematically diagnose children with CKD. As a result, the reported incidence of CKD is widely variable. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – CKD in children is the result of a heterogeneous group of disorders. Congenital disease accounts for 60 percent of CKD cases and includes obstructive uropathy, kidney hypoplasia, and kidney dysplasia. Glomerular disorders are the second largest cause of childhood CKD and are more common in children greater than 12 years of age  (<a class="graphic graphic_figure graphicRef68637" href="/d/graphic/68637.html" rel="external">figure 2</a>). (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CKD progression</strong> – In children, CKD is usually characterized by a progressive deterioration of kidney function, leading to end-stage kidney disease (ESKD). However, the rate of CKD progression is variable and often unpredictable. Risk factors associated with an increased risk of progression of CKD include primary glomerular disease, proteinuria, and hypertension. (See <a class="local">'Progression of chronic kidney disease'</a> above.)</p><p></p><p class="bulletIndent1">Blood pressure (BP) control has been the only intervention that has been shown to have a beneficial effect on slowing CKD progression in children. (See <a class="local">'Blood pressure control'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.</a></li><li><a class="nounderline abstract_t">Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. Nat Rev Dis Primers 2017; 3:17088.</a></li><li><a class="nounderline abstract_t">Coulthard MG. Maturation of glomerular filtration in preterm and mature babies. Early Hum Dev 1985; 11:281.</a></li><li><a class="nounderline abstract_t">Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34:571.</a></li><li><a class="nounderline abstract_t">KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:136.</a></li><li><a class="nounderline abstract_t">Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58:259.</a></li><li><a class="nounderline abstract_t">Counahan R, Chantler C, Ghazali S, et al. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 1976; 51:875.</a></li><li><a class="nounderline abstract_t">Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984; 104:849.</a></li><li><a class="nounderline abstract_t">Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20:629.</a></li><li><a class="nounderline abstract_t">Pierce CB, Muñoz A, Ng DK, et al. Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int 2021; 99:948.</a></li><li><a class="nounderline abstract_t">Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111:1416.</a></li><li><a class="nounderline abstract_t">Filler G, Lee M. Educational review: measurement of GFR in special populations. Pediatr Nephrol 2018; 33:2037.</a></li><li><a class="nounderline abstract_t">Warady BA, Abraham AG, Schwartz GJ, et al. Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort. Am J Kidney Dis 2015; 65:878.</a></li><li><a class="nounderline abstract_t">Fathallah-Shaykh SA, Flynn JT, Pierce CB, et al. Progression of pediatric CKD of nonglomerular origin in the CKiD cohort. Clin J Am Soc Nephrol 2015; 10:571.</a></li><li><a class="nounderline abstract_t">Fuhrman DY, Schneider MF, Dell KM, et al. Albuminuria, Proteinuria, and Renal Disease Progression in Children with CKD. Clin J Am Soc Nephrol 2017; 12:912.</a></li><li><a class="nounderline abstract_t">Furth SL, Pierce C, Hui WF, et al. Estimating Time to ESRD in Children With CKD. Am J Kidney Dis 2018; 71:783.</a></li><li><a class="nounderline abstract_t">Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105:1242.</a></li><li><a class="nounderline abstract_t">El Hamel C, Chianea T, Thon S, et al. Normal values of urine total protein- and albumin-to-creatinine ratios in term newborns. Pediatr Nephrol 2017; 32:113.</a></li><li><a class="nounderline abstract_t">Gluck CA, Forrest CB, Davies AG, et al. Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database. Clin J Am Soc Nephrol 2023; 18:173.</a></li><li><a class="nounderline abstract_t">Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012; 27:363.</a></li><li><a class="nounderline abstract_t">Ploos van Amstel S, Noordzij M, Warady BA, et al. Renal replacement therapy for children throughout the world: the need for a global registry. Pediatr Nephrol 2018; 33:863.</a></li><li class="breakAll">North American Pediatric Renal Trials and Collaborative Studies. 2008 Annual Report. Available at: https://web.emmes.com/study/ped/announce.htm (Accessed on November 07, 2017).</li><li><a class="nounderline abstract_t">White A, Wong W, Sureshkumur P, Singh G. The burden of kidney disease in indigenous children of Australia and New Zealand, epidemiology, antecedent factors and progression to chronic kidney disease. J Paediatr Child Health 2010; 46:504.</a></li><li><a class="nounderline abstract_t">Ng DK, Robertson CC, Woroniecki RP, et al. APOL1-associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts. Nephrol Dial Transplant 2017; 32:983.</a></li><li><a class="nounderline abstract_t">Ardissino G, Daccò V, Testa S, et al. Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 2003; 111:e382.</a></li><li><a class="nounderline abstract_t">Wong CJ, Moxey-Mims M, Jerry-Fluker J, et al. CKiD (CKD in children) prospective cohort study: a review of current findings. Am J Kidney Dis 2012; 60:1002.</a></li><li><a class="nounderline abstract_t">Costigan CS, Rosenblum ND. Antenatally Diagnosed Kidney Anomalies. Pediatr Clin North Am 2022; 69:1131.</a></li><li class="breakAll">United States Renal Data System. 2023 Annual Data Report. Available at: https://usrds-adr.niddk.nih.gov/2023 (Accessed on November 16, 2023).</li><li><a class="nounderline abstract_t">Campanholle G, Ligresti G, Gharib SA, Duffield JS. Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol Cell Physiol 2013; 304:C591.</a></li><li><a class="nounderline abstract_t">Querfeld U, Anarat A, Bayazit AK, et al. The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study: objectives, design, and methodology. Clin J Am Soc Nephrol 2010; 5:1642.</a></li><li><a class="nounderline abstract_t">Shroff R, Aitkenhead H, Costa N, et al. Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD. J Am Soc Nephrol 2016; 27:314.</a></li><li><a class="nounderline abstract_t">Staples AO, Greenbaum LA, Smith JM, et al. Association between clinical risk factors and progression of chronic kidney disease in children. Clin J Am Soc Nephrol 2010; 5:2172.</a></li><li><a class="nounderline abstract_t">Portale AA, Wolf MS, Messinger S, et al. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol 2016; 11:1989.</a></li><li><a class="nounderline abstract_t">Rodenbach KE, Schneider MF, Furth SL, et al. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study. Am J Kidney Dis 2015; 66:984.</a></li><li><a class="nounderline abstract_t">Crump C, Sundquist J, Winkleby MA, Sundquist K. Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study. BMJ 2019; 365:l1346.</a></li><li><a class="nounderline abstract_t">Greenbaum LA, Muñoz A, Schneider MF, et al. The association between abnormal birth history and growth in children with CKD. Clin J Am Soc Nephrol 2011; 6:14.</a></li><li><a class="nounderline abstract_t">Ardissino G, Testa S, Daccò V, et al. Puberty is associated with increased deterioration of renal function in patients with CKD: data from the ItalKid Project. Arch Dis Child 2012; 97:885.</a></li><li><a class="nounderline abstract_t">ESCAPE Trial Group, Wühl E, Trivelli A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361:1639.</a></li><li><a class="nounderline abstract_t">Dionne JM, Jiang S, Ng DK, et al. Mean Arterial Pressure and Chronic Kidney Disease Progression in the CKiD Cohort. Hypertension 2021; 78:65.</a></li></ol></div><div id="topicVersionRevision">Topic 6115 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29168475" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4054047" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Maturation of glomerular filtration in preterm and mature babies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3588043" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/951142" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1008594" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Estimation of glomerular filtration rate from plasma creatinine concentration in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6726515" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A simple estimate of glomerular filtration rate in full-term infants during the first year of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158356" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : New equations to estimate GFR in children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301749" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12777562" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29218435" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Educational review: measurement of GFR in special populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25799137" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Predictors of Rapid Progression of Glomerular and Nonglomerular Kidney Disease in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25635034" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Progression of pediatric CKD of nonglomerular origin in the CKiD cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28546440" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Albuminuria, Proteinuria, and Renal Disease Progression in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29653769" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Estimating Time to ESRD in Children With CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10835064" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27307246" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Normal values of urine total protein- and albumin-to-creatinine ratios in term newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36754006" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluating Kidney Function Decline in Children with Chronic Kidney Disease Using a Multi-Institutional Electronic Health Record Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713524" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Epidemiology of chronic kidney disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29273970" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Renal replacement therapy for children throughout the world: the need for a global registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29273970" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Renal replacement therapy for children throughout the world: the need for a global registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20854321" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The burden of kidney disease in indigenous children of Australia and New Zealand, epidemiology, antecedent factors and progression to chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27190333" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : APOL1-associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12671156" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Epidemiology of chronic renal failure in children: data from the ItalKid project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23022429" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : CKiD (CKD in children) prospective cohort study: a review of current findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36880926" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antenatally Diagnosed Kidney Anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36880926" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antenatally Diagnosed Kidney Anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23325411" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20576824" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study: objectives, design, and methodology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26069294" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Normal 25-Hydroxyvitamin D Levels Are Associated with Less Proteinuria and Attenuate Renal Failure Progression in Children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813855" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Association between clinical risk factors and progression of chronic kidney disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27561289" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209544" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31043374" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21030583" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The association between abnormal birth history and growth in children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22833407" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Puberty is associated with increased deterioration of renal function in patients with CKD: data from the ItalKid Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846849" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Strict blood-pressure control and progression of renal failure in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34058856" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mean Arterial Pressure and Chronic Kidney Disease Progression in the CKiD Cohort.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
